Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device
Roche's VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Mesothelioma Cancer Detection May Improve with New Test
Researchers have developed a novel testing strategy for mesothelioma cancer, focusing on detecting chromosomal rearrangements in cancer DNA.
Lung Cancer
Latest
Breakthrough Lung Cancer Blood Test is 14 Times More Sensitive
A new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
AI Blood Test Reliably Identifies Lung Cancer
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read More
DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
PROphet Platform’s Predictive Ability to be Demonstrated
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
DELFI Collaborates with Hospital System to Improve Lung Cancer Screening
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More
Nucleix’s New Assay May Differentiate Small Cell Lung Cancer Subtypes
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read More
Study Demonstrates Clinical Validity of OncoHost’s NSCLC Test
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read More
Noninvasive Testing Key to Id’ing Lung Cancer
New noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read More
New Epigenomic Technology Platform Predicts Immunotherapy Response in NSCLC Patients
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read More
New ChromaCode Collaboration to Improve NSCLC Biomarker Testing Access
ChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.Â
Read More
New Sensor Technology May Enable Early Lung Cancer Detection
The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read More
Freenome Initiates Clinical Study of Blood Test for Early Lung Cancer Screening
Freenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.Â
Read More
DELFI Diagnostics Supports Legislation for CMS to Review New Lung Cancer Liquid Biopsies
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read More
Liquid Biopsy Predicts Immunotherapy Response, Toxicity in Advanced Lung Cancer Patients
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read More
Veracyte’s Nasal Swab Test Gets Clinical Validation for Lung Cancer Risk Assessment
Clinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read More